Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA 1 5 30 versus PORTIA 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA 1 5 30 versus PORTIA 28.
AUROVELA 1.5/30 vs PORTIA-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combined estrogen-progestin contraceptive: ethinyl estradiol suppresses gonadotropin (FSH, LH) release via negative feedback on pituitary; norethindrone acetate inhibits ovulation by suppressing LH surge, altering cervical mucus and endometrial lining.
Combination oral contraceptive: estrogen (ethinyl estradiol) suppresses gonadotropin release, inhibiting ovulation; progestin (levonorgestrel) alters cervical mucus and endometrial lining.
One tablet (1.5 mg norethindrone acetate, 30 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo.
One tablet (levonorgestrel 0.15 mg, ethinyl estradiol 0.03 mg) orally once daily
None Documented
None Documented
Norethindrone: 8-10 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved within 5-7 days.
Levonorgestrel: 24-30 hours; ethinyl estradiol: 12-15 hours. Clinical context: Steady-state achieved within 5-7 days.
Renal (25% norethindrone metabolites, 5% ethinyl estradiol metabolites) and fecal (60% norethindrone, 30% ethinyl estradiol); <1% unchanged drug in urine.
Renal (60-70% as metabolites, 20-30% as levonorgestrel/ethinyl estradiol glucuronides), fecal (10-20%), biliary (minor).
Category C
Category C
Oral Contraceptive
Oral Contraceptive